NM_000492.4:c.1585-2A>G
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000492.4(CFTR):c.1585-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000492.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.1585-2A>G | splice_acceptor_variant, intron_variant | Intron 11 of 26 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 1431132Hom.: 0 Cov.: 26 AF XY: 0.00 AC XY: 0AN XY: 714046
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:4Other:1
The c.1585-2A>G intronic variant results from an A to G substitution two nucleotides upstream from coding exon 12 in the CFTR gene. This alteration has been identified in multiple individuals diagnosed with cystic fibrosis (Strandvik B et. al. Genet Test. 2001;5(3): 235-242; Frentescu L et al. J Cyst Fibros. 2008;7(5): 423-428; Silva IAL et al. Biochim Biophys Acta Mol Basis Dis, 2020 Nov;1866:165905). In multiple studies, this alteration resulted in skipping of exon 12 and retention of 6 nucleotides in intron 11 (Sharma N et al. Hum Mutat, 2014 Oct;35:1249-59; Silva IAL et al. Biochim Biophys Acta Mol Basis Dis 2020 11;1866(11):165905). Of note, this alteration is also known as 1717-2A>G in published literature. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
This variant was identified in 1 patient with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PVS1, PS1_SUP, PS3_SUP, PM2_SUP, PM3 , PP4 -
Variant summary: The CFTR c.1585-2A>G variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict the complete loss of a canonical splice acceptor site. Functional studies have confirmed the aberrant splicing caused by this variant which includes both the retention of six intronic nucleotides and the skipping of exon 12 (Sharma_2014). This variant is absent in 120436 control chromosomes, and has been reported in CF patients in the literature. Taken together, this variant is classified as pathogenic. -
ClinVar contains an entry for this variant (Variation ID: 53290). This sequence change affects an acceptor splice site in intron 11 of the CFTR gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with cystic fibrosis (PMID: 11788090). This variant is also known as 1717-2A>G. Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 25066652). For these reasons, this variant has been classified as Pathogenic. -
- -
CFTR-related disorder Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at